Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: The UPBEAT study - Rationale, design, and methodological issues

Clinical Trials

Volumn 4, Issue 5, 2007, Pages 548-559

  Blumenthal, James A ^a   Sherwood, Andrew ^a   Rogers, Sharon D ^a   Babyak, Michael A ^a   Doraiswamy, P Murali ^a   Watkins, Lana ^a   Hoffman, Benson M ^a   O'Connell, Cara ^a   Johnson, Julie J ^a   Patidar, Seema M ^a   Waugh, Robert ^a   Hinderliter, Alan ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PLACEBO; SERTRALINE;

ADULT; AEROBIC EXERCISE; ARTICLE; BECK DEPRESSION INVENTORY; BLOOD VESSEL FUNCTION; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FUNDING; HAMILTON SCALE; HEART RATE VARIABILITY; HUMAN; HUMAN CELL; INFLAMMATION; ISCHEMIC HEART DISEASE; KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MORBIDITY; MORTALITY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOM; THROMBOCYTE AGGREGATION; VASODILATATION;

ADULT; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; DEPRESSION; ENDPOINT DETERMINATION; EXERCISE; FEMALE; HEART DISEASES; HUMANS; MALE; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SERTRALINE; UNITED STATES;

EID: 36549069650     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774507083388     Document Type: Article

References (81)

1. American Heart Association. 2001. Heart and stroke statistical update. American Heart Association, Dallas, TX, 2001.
2. Naghavi M, Libby P, Falk E et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108: 1664-72.
3. Naghavi M, Libby P, Falk E et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003; 108: 1772-78.
4. Barefoot JC. Depression and coronary heart disease. Cardiologia 1997; 42: 1245-50.
5. Carney RM, Freedland KE, Sheline YI, Weiss ES. Depression and coronary heart disease: a review for cardiologists. Clin Cardiol 1997; 20: 196-200.
6. Lett H, Blumenthal J, Babyak M, Sherwood A, Strauman T, Robins C. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med 2004; 66: 305-15.
7. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999; 99: 2192-217.
8. Barth J, Schumacher M, Hermann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med 2004; 66: 802-13.
9. van Melle JP, de Jong P, Spijkerman TA et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta analysis. Psychosom Med 2004; 66: 814-22.
10. Davidson KW, Rieckman N, Lesperance F. Psychological theories of depression: potential application for the prevention of acute coronary syndrome recurrence. Psychosom Med 2004; 66: 165-73.
11. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993; 270: 1819-25.
12. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995; 91: 999-1005.
13. Frasure-Smith N, Lesperance F, Juneau M, Talajic M, Bourassa MG. Gender, depression, and one-year prognosis after myocardial infarction. Psychosom Med 1999; 61: 26-37.
14. Lesperance F, Frasure-Smith N, Talajic M, Bourassa MG. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation 2002; 105: 1049-53.
15. Bush DE, Ziegelstein RC, Tayback M et al. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. Am J Cardiol 2001; 88: 337-41.
16. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001; 24: 1069-78.
17. Thakore JH, Richards PJ, Reznek RH, Martin A, Dinan TG. Increased intra-abdominal fat deposition in patients with major depressive illness as measured by computed tomography. Biological Psychiatry 1997; 41: 1140-42.
18. Rich MW, Saini JS, Kleiger RE, Carney RM, Tevelde A, Freedland KE. Correlation of heart rate variability with clinical and angiographic variables and late mortality after coronary angiography. Am J Cardiol 1988; 62: 1-7.
19. Kleiger RE, Miller JP, Bigger Jr, JT, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59: 256-62.
20. Nolan J, Batin PD, Andrews R et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 1998; 98: 1510-16.
21. Carney RM, Saunders RD, Freedland KE, Stein P, Rich MW, Jaffe AS. Association of depression with reduced heart rate variability in coronary artery disease. Am J Cardiol 1995; 76: 562-64.
22. Carney RM, Blumenthal JA, Stein PK et al. Depression, heart rate variability, and acute myocardial infarction. Circulation 2001; 104: 2024-28.
23. Casolo G, Balli E, Taddei T, Amuhasi J, Gori C. Decreased spontaneous heart rate variability in congestive heart failure. Am J Cardiol 1989; 64: 1162-67.
24. Watkins LL, Grossman P. Association of depressive symptoms with reduced baroreflex cardiac control in coronary artery disease. Am Heart J 1999; 137: 453-57.
25. La Rovere MT, Bersano C, Gnemmi M, Specchia G, Schwartz PJ. Exercise-induced increase in baroreflex sensitivity predicts improved prognosis after myocardial infarction. Circulation 2002; 106: 945-49.
26. Hohnloser SH, Klingenheben T, van de LA, Hablawetz E, Just H, Schwartz PJ. Reflex versus tonic vagal activity as a prognostic parameter in patients with sustained ventricular tachycardia or ventricular fibrillation. Circulation 1994; 89: 1068-73.
27. De Ferrari GM, Landolina M, Mantica M, Manfredini R, Schwartz PJ, Lotto A. Baroreflex sensitivity, but not heart rate variability, is reduced in patients with life-threatening ventricular arrhythmias long after myocardial infarction. Am Heart J 1995; 130: 473-80.
28. Billman GE, Schwartz PJ, Stone HL. Baroreceptor reflex control of heart rate: a predictor of sudden cardiac death. Circulation 1982; 66: 874-80.
29. Kennedy GJ, Hofer MA, Cohen D, Shindledecker R, Fisher JD. Significance of depression and cognitive impairment in patients undergoing programed stimulation of cardiac arrhythmias. Psychosom Med 1987; 49: 410-21.
30. Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation 2003; 108: 2093-98.
31. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arteriosclerosis, Thrombosis & Vascular Biology 2003; 23: 168-75.
32. Rajagopalan S, Brook R, Rubenfire M, Pitt E, Young E, Pitt B. Abnormal brachial artery flow-mediated vasodilation in young adults with major depression. Am J Cardiol 2001; 88: 196-98.
33. Broadley AJ, Korszun A, Jones CJ, Frenneaux MP. Arterial endothelial function is impaired in treated depression. Heart (British Cardiac Society) 2002; 88: 521-23.
34. Harris KF, Matthews KA, Sutton-Tyrrell K, Kuller LH. Associations between psychological traits and endothelial function in postmenopausal women. Psychosom Med 2003; 65: 402-09.
35. Sherwood A, Hinderliter AL, Watkins LL, Waugh RA, Blumenthal JA. Impaired endothelial function in coronary heart disease patients with depressive symptomatology. JACC 2005; 46: 656-59.
36. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-12.
37. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. NEJM 2002; 347: 1557-65.
38. Tall AR. C-reactive protein reassessed. NEJM 2004; 350: 1450-52.
39. Ford DE, Erlinger TP. Depression and C-reative protein in US adults. Arch Intern Med 2004; 164: 1010-14.
40. Patrono C, Renda G. Platelet activation and inhibition in unstable coronary syndromes. Am J Cardiol 1997; 80: 17E-20E.
41. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613-17.
42. Markovitz JH, Shuster JL, Chitwood WS, May RS, Tolbert LC. Platelet activation in depression and effects of sertraline treatment: an open-label study. Am J Psychiat 2000; 157: 1006-08.
43. Musselman DL, Tomer A, Manatunga AK et al. Exaggerated platelet reactivity in major depression. Am J Psychiat 1996; 153: 1313-17.
44. Kop WJ, Gottdiener JS, Tangen CM et al. Inflammation and coagulation factors in persons >65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am J Cardiol 2002; 89: 419-24.
45. Laghrissi-Thode F, Wagner WR, Pollock BG, Johnson PC, Finkel MS. Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biological Psychiatry 1997; 42: 290-95.
46. Depression Guideline Panel. Depression in Primary Care, Volume 2. Treatment of Depression, Clinical Practice Guideline, No. 5. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, HHCPR, 1993.
47. Lesperance F, Frasure-Smith N, Koszycki D et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) Trial. JAMA 2007; 297: 367-79.
48. Glassman AH, O'Connor CM, Califf RM et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288: 701-09.
49. Writing Committee for the ENRICHD Investigators. Effects of treating depression and low perceived social support on clinical events after myocardial infarction. JAMA 2003; 289: 3106-16.
50. Taylor CB, Youngblood ME, Catellier D et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005; 62: 792-98.
51. Sherwood A, Blumenthal JA, Trivedi R et al. Relationship of depression to death or hospitalization in patients with heart failure. Arch Int Med 2007; 167: 367-73.
52. Carney RM, Blumenthal JA, Freedland KE et al. Depression and late mortality after myocardial infarction in the enhancing recovery in coronary heart disease (ENRICHD) Study. Psychosom Med 2004; 66: 466-74.
53. Brosse AL, Sheets ES, Lett HS, Blumenthal JA. Exercise and the treatment of clinical depression in adults: recent findings and future directions. Sports Medicine 2002; 32: 741-60.
54. Folkins CH, Sime WE. Physical fitness training and mental health. Am Psychologist 1981; 36: 373-89.
55. Hughes JR. Psychological effects of habitual aerobic exercise: a critical review. Prev Med 1984; 13: 66-78.
56. Greist JH, Klein M. Running as a treatment for depression. Comp Psychiat 1979; 20: 41-54.
57. Lawlor DA, Hopker SW. The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials. Br Med J 2001; 322: 763-67.
58. Blumenthal JA, Babyak MA, Moore KA et al. Effects of exercise training on older patients with major depression. Arch Int Med 1999; 159: 2349-56.
59. Dunn AL, Trivedi MH, Kampert JB, Clark CG, Chambliss HO. Exercise treatment for depression: Efficacy and dose response. Am J Prev Med 2005; 28: 1-8.
60. Blumenthal JA, Babyak MA, Carney RM et al. Exercise, depression, and mortality after myocardial infarction in the ENRICHD trial. Medicine and Science in Sports and Exercise 2004; 36: 746-55.
61. Bigger Jr, JT, Albrecht P, Steinman RC, Rolnitzky LM, Fleiss JL, Cohen RJ. Comparison of time- and frequency domain-based measures of cardiac parasympathetic activity in Holter recordings after myocardial infarction. Am J Cardiol 1989; 64: 536-38.
62. Bigger Jr. JT, Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992; 85: 164-71.
63. Welch PD. The use of fast Fourier transform for the estimation of power spectra: a method based on time averaging over short modified periodograms. IEEE Trans Audio Electroacoust 1967; 15: 70-73.
64. Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-15.
65. Corretti MC, Anderson TJ, Benjamin EJ et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task. JACC 2002; 39: 257-65.
66. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. JACC 1994; 24: 1468-74.
67. Kuipers PM, Hamauluak K. β Thromboglobulin and platelet factor 4 levels in post-MI patients with major depression. Psychiat Res 2002; 109: 207-10.
68. Martinez-Sales V, Vila V, Reganon E, Goberna MA et al. Elevated thrombotic activity after myocardial infarction: a 2-year follow-up study. Haemostasis 1998; 28: 301-6.
69. Serebruany VL, Glassman AH, Malinin AI et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline Anti-Depressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003; 108: 939-44.
70. Muthen B. A general structural equation model with dichotomous, ordered categorical, and continuous latent variable indicators. Psychometrika 1984; 49: 115-32.
71. Blumenthal JA, Sherwood A, Babyak MA et al. Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease; a randomized controlled trial. JAMA 2005; 293(13): 1626-34.
72. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc, Series B 1995; 57: 289-300.
73. Levine R. The use of placebos in randomized clinical trials. IRB 1985; 7: 1-4.
74. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. NEJM 1994; 331: 394-8.
75. Addington D, Williams R, Lapierre Y, el Guebaly N. Placebos in clinical trials of psychotropic medication. Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie 1997; 42: 1-6.
76. Bialik RJ, Ravindran AV, Bakish D, Lapierre YD. A comparison of placebo responders and nonresponders in subgroups of depressive disorder. J Psychiat & Neurosci 1995; 20: 265-70.
77. Klein DF. Preventing hung juries about therapy studies. J Consult & Clin Psychol 1996; 64: 81-87.
78. Klerman GL. Scientific and ethical considerations in the use of placebo controls in clinical trials in psychopharmacology. Psychopharmacol Bull 1986; 22: 25-29.
79. Prien RF. Method and models for placebo use in pharmacotherapeutic trials. Psychopharmacol Bull 1988; 24: 4-8.
80. Temple R. Difficulties in evaluating positive control trials. Clinic Eval 1993; 21: 141-149.
81. Rozanski A, Blumenthal JA, Davidson KW, Saab PG, Kubzansky L. The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice. JACC 2005; 45: 637-51.